November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Elvina Almuradova: FDA approves Zanidatama for HER2+ biliary tract cancer
Nov 24, 2024, 18:03

Elvina Almuradova: FDA approves Zanidatama for HER2+ biliary tract cancer

Elvina Almuradova, Associate Professor at Medicana Health Group, shared a post on X:

FDA approves Zanidatama for HER2+ biliary tract cancer based on HERIZON-BTC-01 trial results:

  • ORR: 52%
  • DOR: 14.9 months
  • First dual HER2-targeted bispecific antibody for BTC

The confirmatory Phase III trial is ongoing.”

Elvina Almuradova: FDA approves Zanidatama for HER2+ biliary tract cancer

Read more about the FDA approval of Zanidatama on oncodaily.com.

More posts featuring Elvina Almuradova.